All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Dermatology Drugs in Phase I Clinical Development in ISRAEL

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

BiomX

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

World Dairy Expo

Participation Not Confirmed

Update your events

BiomX Discloses Acne Pre-clinical Data Planned for 2020 AAD Annual Meeting

Contact the Supplier

Lead Product(s): BX001

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 20, 2020

Details:

BiomX is developing BX001, its lead product candidate, to modify the appearance of acne prone skin.

Sol-Gel Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

World Dairy Expo

Participation Not Confirmed

Update your events

Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)

Contact the Supplier

Lead Product(s): SGT-210

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 02, 2020

Details:

The Phase 1 proof of concept study SGT-84-01 is a single-center, single-blinded, vehicle-controlled study designed to evaluate the bioavailability, safety, tolerability and efficacy of SGT-210.